ReviewFrontiers in pharmacology2026
Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exosome-Mediated Systemic Signaling: Mechanisms, Disease Integration, and Translational Potential.Current issues in molecular biology · 2026Review
- MicroRNAs: A Social Network in Diabetic Retinopathy.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic microvascular complications, including diabetic kidney disease, diabetic retinopathy, and diabetic peripheral neuropathy, are associated with a growing burden and frequently present as comorbidities, posing substantial therapeutic challenges. Exosomes have been identified as key drivers in the pathogenesis of these conditions by mediating cell-cell communication. This review summarizes the biogenesis, cargo sorting, and uptake of exosomes, with emphasis on how these processes are reprogrammed under metabolic stress, converting exosomes from physiological regulators into carriers of pathological signals. A focused analysis is provided on how metabolic stress reshapes exosomal cargo profiles in each complication, leading to the enrichment of specific microRNAs, proteins, and lipids. These pathological exosomes establish aberrant communication networks among renal, retinal, and neural cells, through which inflammatory responses, oxidative stress, apoptosis, and fibrosis are amplified and vascular injury signals are transmitted, forming self-reinforcing pathological cycles. Exosomes also hold significant promise for clinical translation. Exosomes derived from body fluids carry molecules from injured cells and can serve as non-invasive biomarkers for early diagnosis. Exosome-based therapeutic strategies, particularly those involving stem cell-derived exosomes or exosomes modulated by antidiabetic drugs and natural products, offer multi-target approaches for microvascular intervention. Current challenges include elucidating cross-organ communication networks in comorbid conditions, advancing clinical standardization of exosomal biomarkers, and developing engineered exosomes for precision therapy. An exosome-mediated cell-cell communication perspective provides a more integrated framework for understanding diabetic microvascular comorbidities and may inform the development of multi-complication co-targeting strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.